On both sides of the Atlantic, brand-name drug companies have paid generics to delay entering the market. The week of June 17, 2013 will go down as potentially the most important week ever in the history of challenges to this activity.

On Monday, the U.S. Supreme Court found that such “pay for delay” (or “reverse payment”) agreements could present violations of the antitrust laws. And on Wednesday, the European Commission (EC) for the first time issued a fine against companies that enter into such settlements.

This post for Infojustice summarizes and analyzes these developments.http://infojustice.org/archives/29992